Blueprint Medicines Corp (NASDAQ:BPMC) announced that it will present new preclinical data demonstrating the potential utility of BLU-285 in a subset of patients with …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today provided an update …
Blueprint Medicines Corp (NASDAQ:BPMC) announced that the U.S.
Blueprint Medicines Corp (NASDAQ:BPMC) announced that it will present preclinical data on its drug candidate BLU-554 in hepatocellular carcinoma (HCC), as well as on …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today reported financial results and provided …
Blueprint Medicines Corp (NASDAQ:BPMC) has been reiterated as an Outperform at Wedbush by research analyst David Nierengarten in a recent report released yesterday. The …
Cowen’s healthcare analyst Eric Schmidt came out today with a research note on Blueprint Medicines Corp (NASDAQ:BPMC), after the company announced that the FDA accepted the Company’s Investigational …
Blueprint Medicines Corp (NASDAQ:BPMC) is a Cambridge-MA-based biotech firm working to develop cancer treatment therapies by analyzing kinase mutations in cells. (Kinases are …
